Clinical Trials in Boston

Showing 1541-1560 of 8,503 trials

Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness

NCT03814356

Phase 1 of the STIMPACT trial is an open label,dose-escalation,safety study of intravenous (IV) methylphenidate (MPH) therapy in patients with disorders of consciousness (DoC) caused by severe brain injuries.

Brain Injury Traumatic Severe (Diagnosis)ComaConsciousness, Level Altered+1 more

Massachusetts General Hospital10 participantsStarted Aug 2020

Boston, Massachusetts, United States

RECRUITING< 1 mile

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

NCT05265429

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

Non Small Cell Lung CancerSmall Cell Lung CarcinomaNUT Carcinoma

Dana-Farber Cancer Institute500 participantsStarted Jan 2023

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +1 more locations

RECRUITINGNA< 1 mile

Access Cannulation Trial II

NCT05490225

This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.

Dialysis; ComplicationsVascular Access Complication

Voyager Biomedical100 participantsStarted Apr 2025

Dothan, Alabama, United States • Riverside, California, United States • Boston, Massachusetts, United States +5 more locations

Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Access Cannulation Trial II

Find Trials by Condition in Boston

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

A Study of XMT-1660 in Participants With Solid Tumors

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Safety and Effectiveness Study of OR3O™ Dual Mobility System in THA

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Pediatric Patients Aged 4 to 11 Years With APDS

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Stryker's Surgeon iD Mandible Reconstruction Plates: A Retrospective Post Market Follow Up